Watson David O. (CIK 1657719) reported 36 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-14). Recent activity: Sell APLS (55,986 shares), Sell APLS (7,363 shares), Sell APLS (50,136 shares), Buy APLS (41,250 shares), Sell APLS (41,250 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 55,986 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 7,363 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 50,136 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Buy | 41,250 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 41,250 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Buy | 28,508 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 28,508 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 10,000 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 27,993 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Buy | 55,986 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 144,517 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 32,072 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 55,986 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 11,874 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 6,001 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Buy | 27,993 | $0 |
| 2026-01-30 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Buy | 55,986 | $0 |
| 2026-01-23 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 7,832 | $170,503 |
| 2026-01-21 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 2,475 | $48,980 |
| 2026-01-15 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 5,780 | $128,258 |
| 2026-01-09 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Buy | 888 | $13,276 |
| 2025-12-18 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 5,000 | $122,450 |
| 2025-11-18 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 5,000 | $100,300 |
| 2025-10-17 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 5,000 | $126,100 |
| 2025-09-18 | Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | Sell | 5,000 | $121,700 |
Source: SEC Form 4 filings · as of 2026-05-14